FdaApplication
NDA 202236
Identifiers
- fda_app_no: NDA202236
Properties
| Property | Value |
|---|---|
| applicant_name | MYLAN SPECIALTY LP |
| application_type | NDA |
| approval_date | 2012-05-01 |
Revenue by product
DYMISTA
| Period | Revenue |
|---|---|
| Q2 2026 | $39.8M* |
| Q1 2026 | $37.3M* |
| Q4 2025 | $38.6M* |
| Q3 2025 | $33.8M* |
| Q2 2025 | $48.4M* |
| Q1 2025 | $42.8M* |
| Q4 2024 | $41.3M* |
| Q3 2024 | $43.5M* |
| Q2 2024 | $55.0M* |
| Q1 2024 | $48.2M* |
| Q4 2023 | $45.0M* |
| Q3 2023 | $44.1M* |
| Q2 2023 | $57.7M* |
| Q1 2023 | $53.2M* |
| Q4 2022 | $41.8M* |
| Q3 2022 | $38.6M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DYMISTA | AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE | 0.137MG/SPRAY;0.05MG/SPRAY | SPRAY, METERED;NASAL |
1 product